Dual treatment with a fixed ratio of glucagon and insulin increases the therapeutic window of insulin in diabetic rats

The current available insulin therapies decrease blood glucose but are associated with the risk of developing hypoglycemia. Glucagon is a counter regulatory hormone and we hypothesize that a fixed ratio of insulin and a long‐acting glucagon‐analogue can reduce the risk of hypoglycemia. To define an...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedersen, Christina, Bouman, Stephan D., Porsgaard, Trine, Rosenkilde, Mette M., Roed, Nikolaj K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875541/
https://www.ncbi.nlm.nih.gov/pubmed/29595915
http://dx.doi.org/10.14814/phy2.13657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875541/
https://www.ncbi.nlm.nih.gov/pubmed/29595915
http://dx.doi.org/10.14814/phy2.13657

Ejemplares similares